Updates in the Treatment of Breakthrough Mold Infections

Goodlet, Kellie J.; Spadafora, Kelsey; Walia, Rajat; Nailor, Michael D

doi:10.1007/s12281-020-00387-2

Cited by 2 publications

(2 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study indicate that the implementation of thymoquinone, ocimene, or miramistin hydrogel wound dressings may depreciate the need to use other systemic antifungal compounds in the treatment of superficial and deep tissue wounds, which is also in line with currently antimicrobial stewardship agendas and has been developed to specifically target and reduce the incidence of antimicrobial resistance [71]. Prolonged states of trauma are usually associated with inappropriate therapy, which is well documented in being a causative factor toward the development of antimicrobial resistance [72,73]. The issue of antifungal resistance and the need to develop newer and more efficacious products was highlighted by The World Health Organisation in 2020 during the first meeting of the WHO antifungal expert group tasked with identifying priority fungal pathogens and subsequent treatment options [6].…”

Section: Conclusion and Future Prospectsmentioning

confidence: 85%

Advances in Polymeric Materials for Biomedical Applications

2022

View full text Add to dashboard Cite

show abstract

Section: Conclusion and Future Prospectsmentioning

confidence: 85%

Advances in Polymeric Materials for Biomedical Applications

2022

View full text Add to dashboard Cite

show abstract

“…The results of this study indicate that the implementation of thymoquinone, ocimene, or miramistin hydrogel wound dressings may depreciate the need to use other systemic antifungal compounds in the treatment of superficial and deep tissue wounds, which is also in line with currently antimicrobial stewardship agendas and has been developed to specifically target and reduce the incidence of antimicrobial resistance [ 71 ]. Prolonged states of trauma are usually associated with inappropriate therapy, which is well documented in being a causative factor toward the development of antimicrobial resistance [ 72 , 73 ]. The issue of antifungal resistance and the need to develop newer and more efficacious products was highlighted by The World Health Organisation in 2020 during the first meeting of the WHO antifungal expert group tasked with identifying priority fungal pathogens and subsequent treatment options [ 6 ].…”

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

The Mould War: Developing an Armamentarium against Fungal Pathogens Utilising Thymoquinone, Ocimene, and Miramistin within Bacterial Cellulose Matrices

et al. 2021

View full text Add to dashboard Cite

An increase in antifungal resistance has seen a surge in fungal wound infections in patients who are immunocompromised resulting from chemotherapy, disease, and burns. Human pathogenic fungi are increasingly becoming resistant to a sparse repertoire of existing antifungal drugs, which has given rise to the need to develop novel treatments for potentially lethal infections. Bacterial cellulose (BC) produced by Gluconacetobacter xylinus has been shown to possess many properties that make it innately useful as a next-generation biopolymer to be utilised as a wound dressing. The current study demonstrates the creation of a pharmacologically active wound dressing by loading antifungal agents into a biopolymer hydrogel to produce a novel wound dressing. Amphotericin B is known to be highly hepatotoxic, which reduces its appeal as an antifungal drug, especially in patients who are immunocompromised. This, coupled with an increase in antifungal resistance, has seen a surge in fungal wound infections in patients who are immunodeficient due to chemotherapy, disease, or injury. Antifungal activity was conducted via Clinical & Laboratory Standards Institute (CLSI) M27, M38, M44, and M51 against Candida auris, Candida albicans, Aspergillus fumigatus, and Aspergillus niger. This study showed that thymoquinone has a comparable antifungal activity to amphotericin B with mean zones of inhibition of 21.425 ± 0.925 mm and 22.53 ± 0.969 mm, respectively. However, the mean survival rate of HEp-2 cells when treated with 50 mg/L amphotericin B was 29.25 ± 0.854% compared to 71.25 ± 1.797% when treated with 50 mg/L thymoquinone. Following cytotoxicity assays against HEp-2 cells, thymoquinone showed a 71.25 ± 3.594% cell survival, whereas amphotericin B had a mean cell survival rate of 29.25 ± 1.708%. The purpose of this study was to compare the efficacy of thymoquinone, ocimene, and miramistin against amphotericin B in the application of novel antifungal dressings.

show abstract

Updates in the Treatment of Breakthrough Mold Infections

Cited by 2 publications

References 113 publications

Advances in Polymeric Materials for Biomedical Applications

Advances in Polymeric Materials for Biomedical Applications

The Mould War: Developing an Armamentarium against Fungal Pathogens Utilising Thymoquinone, Ocimene, and Miramistin within Bacterial Cellulose Matrices

Contact Info

Product

Resources

About